Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline to Help InforSense, Spotfire Co-develop Software

NEW YORK, May 17 (GenomeWeb News) - InforSense, Spotfire, and GlaxoSmithKline have begun a pilot project to co-develop software for certain data-management applications in drug discovery, the companies said today.


The alliance will lead to a product that Spotfire and InforSense will commercialize before the end of the year, a spokeswoman for Spotfire said.


The collaboration will marry Glaxo's experience building web services to scientific systems; Spotfire's knowledge of visual analytic applications; and InforSense's background in workflow-based integrative analytics, the companies said. 


The deal is meant to engage the concept of "effectively orchestrating web services, disparate data sources, and interactive end-user applications across a large enterprise," Christopher Ahlberg, CEO of Spotfire, said in a statement.


Financial details were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.